WebFeb 2, 2024 · Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes WebJun 25, 2024 · LEXINGTON, Mass., June 25, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today ...
XXVI. Poncii de Jardino, Arnaldum de Jardino, coadiutorem, 1301
WebJun 10, 2024 · Curis scientists discover novel IRAK4 nuclear localization and describe potential use as a biomarker. IRAK4 along with NF-kB p50/p65 localization to the nucleus is associated with improved ... WebMay 12, 2024 · Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise ... howipotq scanner
Patient death triggers a second clinical hold for Curis as FDA seeks ...
WebDec 7, 2024 · Curis Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's ... WebJun 4, 2024 · Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the presentation of encouraging clinical data ... WebApr 19, 2024 · LEXINGTON, Mass., April 19, 2024 /PRNewswire/ -- Curis, Inc. , (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for CA-4948, a first-in-class, small molecule ... high high high 2022 セトリ